search
Back to results

The Effect of an Anti-inflammatory Diet in Patients With Rheumatoid Arthritis (DAIAR)

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Not Applicable
Locations
Portugal
Study Type
Interventional
Intervention
Diet Control
Diet anti-inflammatory
Sponsored by
Universidade Nova de Lisboa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring Anti-inflammatory diet, Disease activity, Quality of life, Rheumatoid arthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age over 18 years;
  • Presence of active disease, (DAS28≥ 2.6), under adequate control and medication.
  • Able to sign informed consent

Exclusion Criteria:

  • Any type of psychological deficiency, dementia or eating disorder;
  • Presence of food allergies and / or intolerances;
  • Be vegetarian or use Phytotherapy or other supplements (namely, pre and probiotics);
  • Use of antibiotics im the last 6 months;
  • Have had previous nutritional monitoring or change in eating habits in the last 6 months.

Sites / Locations

  • Hospital Particular do Algarve - HPA Saúde

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Diet Control

Diet Anti-inflammatory

Arm Description

Diet Control (DC): nutritional education and adherence monitoring. DC will be based on the Portuguese "Nova Roda dos Alimentos" following the principles of the Mediterranean diet.

Diet Anti-inflammatory (DAI): nutritional education and adherence monitoring. The DAI dietary intervention will be based on combining individual food items described as potential anti-inflammatory mitigators.

Outcomes

Primary Outcome Measures

Changes in disease activity
Difference between the intervention and control group in the changes in Disease Activity (using DAS28 score: greater than 2,6 implies active disease), from baseline to the end of follow-up
Changes in Quality of Life
Difference between the intervention and control group in changes in Quality of Life (Health Assessment Questionnaire (HAQ): scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability), from baseline to the end of follow-up

Secondary Outcome Measures

Changes in C-Reactive Protein (CRP)
Difference between the intervention and control group in changes in C-Reactive Protein (CRP) measured in mg/L, from baseline to the end of follow-up
Changes in Erythrocyte Sedimentation Rate (ESR)
Difference between the intervention and control group in changes in Erythrocyte Sedimentation Rate (ESR) measured in mm/h, from baseline to the end of follow-up
Changes in Rheumatoid Factor (RF)
Difference between the intervention and control group changes in Rheumatoid Factor (RF) measured in IU/mL, from baseline to the end of follow-up
Changes in Gut microbiota
Difference between the intervention and control group in the change of gut microbiota from baseline to the end of follow-up. Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.
Changes in weight
Difference between the intervention and control group changes in weight, measured in Kg, from baseline to the end of follow-up
Changes in Body Mass Index (BMI)
Difference between the intervention and control group changes in BMI, calculated using weight and height, presented in kg/m2: underweight < 18,5; normoweight 18,6-24,9; overweight 25-29,9; obese >30, from baseline to the end of follow-up
Changes in waist circumference perimeter
Difference between the intervention and control group changes in waist circumference perimeter, measured in cm, from baseline to the end of follow-up

Full Information

First Posted
March 25, 2022
Last Updated
April 19, 2022
Sponsor
Universidade Nova de Lisboa
Collaborators
Hospital Particular do Algarve - HPA Saúde
search

1. Study Identification

Unique Protocol Identification Number
NCT05336513
Brief Title
The Effect of an Anti-inflammatory Diet in Patients With Rheumatoid Arthritis
Acronym
DAIAR
Official Title
The Effect of an Anti-inflammatory Diet on Disease Activity and Quality of Life in Patients With Rheumatoid Arthritis - Parallel Controlled Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
April 1, 2021 (Actual)
Primary Completion Date
December 20, 2021 (Actual)
Study Completion Date
December 20, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universidade Nova de Lisboa
Collaborators
Hospital Particular do Algarve - HPA Saúde

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Rheumatoid arthritis (RA) is an autoimmune disease that affects 0.5-1% of the population and in which his remission is not always achieved, affecting physical and mental well-being and quality of life (QL). As a complement to pharmacotherapy, dietary intervention should be evaluated as a treatment option. The main objective of this parallel controlled randomized clinical trial is to check the effect of an anti-inflammatory dietary intervention, compared to a diet based on the principles of the Mediterranean diet (control), on disease activity (AD) and improving QL. Patients will be instructed to follow an anti-inflammatory diet (DAI) or a control diet (DC) for 6 months. The AD and QL will be evaluated at the end of the intervention. As there are no dietary guidelines for RA, this study aims to provide scientific evidence about the impact of diet therapy on reducing AD and improving QL.
Detailed Description
The main objective of this trial is to check the effect of an DAI, compared to a DC, on reducing AD and improving QL. As secondary objectives, it is intended to investigate the relationship of DAI with inflammatory markers and with the modulation of the composition / diversity of the intestinal microbiota, in comparison with a DC. This study combines all dietary components with an anti-inflammatory effect, thus allowing the possibility of evaluating the full potential of dietary treatment in the disease, including intestinal microbiota modulation. These results are intended to further contribute to clinical decision making and better evidence-based treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis
Keywords
Anti-inflammatory diet, Disease activity, Quality of life, Rheumatoid arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Diet Control
Arm Type
Other
Arm Description
Diet Control (DC): nutritional education and adherence monitoring. DC will be based on the Portuguese "Nova Roda dos Alimentos" following the principles of the Mediterranean diet.
Arm Title
Diet Anti-inflammatory
Arm Type
Experimental
Arm Description
Diet Anti-inflammatory (DAI): nutritional education and adherence monitoring. The DAI dietary intervention will be based on combining individual food items described as potential anti-inflammatory mitigators.
Intervention Type
Other
Intervention Name(s)
Diet Control
Intervention Description
Diet following mediterranean principles, for 15 weeks
Intervention Type
Other
Intervention Name(s)
Diet anti-inflammatory
Intervention Description
Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.
Primary Outcome Measure Information:
Title
Changes in disease activity
Description
Difference between the intervention and control group in the changes in Disease Activity (using DAS28 score: greater than 2,6 implies active disease), from baseline to the end of follow-up
Time Frame
15 weeks
Title
Changes in Quality of Life
Description
Difference between the intervention and control group in changes in Quality of Life (Health Assessment Questionnaire (HAQ): scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability), from baseline to the end of follow-up
Time Frame
15 weeks
Secondary Outcome Measure Information:
Title
Changes in C-Reactive Protein (CRP)
Description
Difference between the intervention and control group in changes in C-Reactive Protein (CRP) measured in mg/L, from baseline to the end of follow-up
Time Frame
15 weeks
Title
Changes in Erythrocyte Sedimentation Rate (ESR)
Description
Difference between the intervention and control group in changes in Erythrocyte Sedimentation Rate (ESR) measured in mm/h, from baseline to the end of follow-up
Time Frame
15 weeks
Title
Changes in Rheumatoid Factor (RF)
Description
Difference between the intervention and control group changes in Rheumatoid Factor (RF) measured in IU/mL, from baseline to the end of follow-up
Time Frame
15 weeks
Title
Changes in Gut microbiota
Description
Difference between the intervention and control group in the change of gut microbiota from baseline to the end of follow-up. Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.
Time Frame
15 weeks
Title
Changes in weight
Description
Difference between the intervention and control group changes in weight, measured in Kg, from baseline to the end of follow-up
Time Frame
15 weeks
Title
Changes in Body Mass Index (BMI)
Description
Difference between the intervention and control group changes in BMI, calculated using weight and height, presented in kg/m2: underweight < 18,5; normoweight 18,6-24,9; overweight 25-29,9; obese >30, from baseline to the end of follow-up
Time Frame
15 weeks
Title
Changes in waist circumference perimeter
Description
Difference between the intervention and control group changes in waist circumference perimeter, measured in cm, from baseline to the end of follow-up
Time Frame
15 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age over 18 years; Presence of active disease, (DAS28≥ 2.6), under adequate control and medication. Able to sign informed consent Exclusion Criteria: Any type of psychological deficiency, dementia or eating disorder; Presence of food allergies and / or intolerances; Be vegetarian or use Phytotherapy or other supplements (namely, pre and probiotics); Use of antibiotics im the last 6 months; Have had previous nutritional monitoring or change in eating habits in the last 6 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ana Faria, PhD
Organizational Affiliation
Universidade Nova de Lisboa
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Particular do Algarve - HPA Saúde
City
Portimão
Country
Portugal

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Effect of an Anti-inflammatory Diet in Patients With Rheumatoid Arthritis

We'll reach out to this number within 24 hrs